In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Start-Up Previews, July 2015

Executive Summary

This month's profiles: InPress Technologies, MaRVis Medical, Medherant, Molecular Assemblies, MyoPowers, Potrero Medical, Revolution Medicines, and Rivanna Medical

You may also be interested in...

MyoPowers Medical Technologies SAS

French start-up MyoPowers Medical Technologies SAS aims to treat stress urinary incontinence with Artus, a permanent active implant designed to support the natural urinary sphincter and restore urinary continence.

MaRVis Medical GMBH

The growing trend of using magnetic resonance imaging for enhanced visualization is being augmented by MR-safe guidewires, but an MR-safe medical device must be non-ferromagnetic, must neither heat up nor be electrically conductive, and should not create imaging artifacts that obscure or distort the target image. A portfolio of MR-safe guidewires from Germany-based MaRVis Medical GMBH fulfills these requisites by successfully integrating good mechanical and visualization properties.

InPress Technologies Inc.

There are approximately 140,000 fatalities a year from postpartum hemorrhage, mostly in low- to middle-income countries, and thus a pressing need to reduce mortality. A new low-pressure suction device from InPress Technologies Inc. that is inserted into the uterus following childbirth has the potential to initiate blood control within two minutes and reach full restoration of uterine tone in just over two hours.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts